

FINANCIAL STATEMENT AND RELATED ANNOUNCEMENT FOR THE FIRST QUARTER ENDED 31 MARCH 2019

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF YEAR AND FULL YEAR RESULTS

1(a) An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Consolidated Statement of Profit or Loss	Q1 2019	Q1 2018	Change
	S\$'000	S\$'000	%
Revenue	128,291	120,189	6.7
Other operating income	686	1,293	(46.9)
Inventories and consumables used	(15,380)	(14,318)	7.4
Purchased and contracted services	(13,228)	(9,244)	43.1
Staff costs	(66,041)	(63,376)	4.2
Depreciation of property, plant and equipment	(6,182)	(4,015)	54.0
Amortisation of intangible assets	(347)	(361)	(3.9)
Operating lease expenses	(1,747)	(3,393)	(48.5)
Impairment loss on trade receivables	(768)	(753)	2.0
Other operating expenses	(8,177)	(7,131)	14.7
Profit from operating activities	17,107	18,891	(9.4)
Finance income	380	157	nm
Finance expenses	(465)	(191)	nm
Profit before tax	17,022	18,857	(9.7)
Tax expense	(3,295)	(3,391)	(2.8)
Profit for the period	13,727	15,466	(11.2)
Profit attributable to :			
Owners of the Company	13,649	15,812	(13.7)
Non-controlling interests	78	(346)	nm
Profit for the period	13,727	15,466	(11.2)

Note: nm denotes not meaningful

1(a) An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd).

	Q1 2019	Q1 2018	Change
	S\$'000	S\$'000	%
Consolidated statement of comprehensive income			
Profit for the period	13,727	15,466	(11.2)
Other comprehensive income			
Items that are or may be reclassified subsequently to profit or loss:			
Foreign currency translation differences - foreign operations	3,715	1,636	(nm)
Total comprehensive income for the period	<u>17,442</u>	<u>17,102</u>	2.0
Total comprehensive income attributable to:			
Owners of the company	17,008	17,132	(0.7)
Non-controlling interests	434	(30)	(nm)
Total comprehensive income for the period	<u>17,442</u>	<u>17,102</u>	2.0

Note: nm denotes not meaningful

Explanatory notes to the Consolidated Statement of Profit or Loss

- Other operating income decreased mainly due to lower wage credit received.
- More purchased and contracted services were mainly attributed to higher insurance claims in tandem with increased insurance premiums.
- Depreciation increased mainly due to the recognition of right-of-use assets as a result of the adoption of the new Singapore Financial Reporting Standards (International) (SFRS(I)) 16 *Leases*.
- Decrease in operating lease expenses was mainly due to the adoption of the new SFRS(I) 16 *Leases*, which result in a corresponding increase for depreciation.
- Increased other operating expenses were due mainly to building and related expenses of Raffles Hospital Chongqing and Raffles Specialist Centre.
- Profit from operating activities before taxation includes the following:

	Q1 2019	Q1 2018
Group	S\$'000	S\$'000
(a) Other operating income		
Gain on disposal of property, plant and equipment	-	44
Foreign exchange gain	-	365
(b) Other operating expenses		
Recovery of bad debts	(91)	(458)
Property, plant and equipment written off	8	45
Write-off for stock obsolescence	38	42
Foreign exchange loss	38	-

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

Statements of Financial Position	Group		Company	
	31/03/2019 S\$'000	31/12/2018 S\$'000	31/03/2019 S\$'000	31/12/2018 S\$'000
Non-current assets				
Property, plant and equipment	615,322	565,716	9,143	5,808
Intangible assets and goodwill	37,620	37,287	1,127	1,167
Investment properties	311,167	311,160	-	-
Subsidiaries	-	-	568,927	562,604
Deferred tax assets	1,133	1,011	-	-
Trade and other receivables	2,001	2,590	5,769	5,869
	<u>967,243</u>	<u>917,764</u>	<u>584,966</u>	<u>575,448</u>
Current assets				
Inventories	9,886	9,320	2,445	2,341
Trade and other receivables	93,911	83,221	138,031	151,955
Cash and cash equivalents	111,825	105,984	18,945	2,609
	<u>215,622</u>	<u>198,525</u>	<u>159,421</u>	<u>156,905</u>
Total assets	<u>1,182,865</u>	<u>1,116,289</u>	<u>744,387</u>	<u>732,353</u>
Equity attributable to owners of the Company				
Share capital	365,928	365,332	365,928	365,332
Reserves	452,559	435,157	292,378	290,560
	<u>818,487</u>	<u>800,489</u>	<u>658,306</u>	<u>655,892</u>
Non-controlling interests	16,571	16,137	-	-
Total equity	<u>835,058</u>	<u>816,626</u>	<u>658,306</u>	<u>655,892</u>
Non-current liabilities				
Loans and borrowings	106,694	97,189	20,849	20,775
Trade and other payables	12,116	11,380	9,906	868
Finance lease liabilities	13,256	-	2,531	-
Deferred tax liabilities	4,757	4,765	644	644
	<u>136,823</u>	<u>113,334</u>	<u>33,930</u>	<u>22,287</u>
Current liabilities				
Loans and borrowings	19,327	19,307	19,327	19,307
Current tax liabilities	15,620	13,583	1,453	1,573
Trade and other payables	139,533	136,789	30,224	33,294
Finance lease liabilities	6,174	-	1,147	-
Other financial liabilities	2,774	2,790	-	-
Insurance contract provisions	27,556	13,860	-	-
	<u>210,984</u>	<u>186,329</u>	<u>52,151</u>	<u>54,174</u>
Total liabilities	<u>347,807</u>	<u>299,663</u>	<u>86,081</u>	<u>76,461</u>
Total equity and liabilities	<u>1,182,865</u>	<u>1,116,289</u>	<u>744,387</u>	<u>732,353</u>

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year. (Cont'd)

Explanatory notes to the Statement of Financial Position

1. Property, plant and equipment increased by S\$49.6 million, largely due to the capital development expenditure for Raffles Hospital Chongqing and Raffles Hospital Shanghai as well as the recognition of right-of-use asset resulting from the adoption of the new SFRS(I) 16 Leases.
2. Trade and other receivables increased mainly due to billings for premium from the Group's insurance business.
3. The Group's net debt position increased from S\$10.5 million as at 31 December 2018 to S\$14.2 million as at 31 March 2019. This was primarily due to project expenditure incurred for Raffles Hospital Shanghai and Raffles Hospital Chongqing.
4. The increase in loans and borrowings was due to bank loans obtained to finance the project expenditure incurred for Raffles Hospital Shanghai and Raffles Hospital Chongqing.
5. Finance lease liabilities arose from the adoption of the new SFRS(I) 16 Leases. The lease liabilities relate to the present value of future lease payment due to the lessors.
6. Insurance contract provisions increased by S\$13.7 million, mainly due to higher provision for unearned premiums resulting from billings for premium from the Group's insurance business.

1(b)(ii) Aggregate amount of group's borrowings and debt securities.

Amount repayable in one year or less, or on demand

As at 31/03/2019		As at 31/12/2018	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	19,327	-	19,307

Amount repayable after one year

As at 31/03/2019		As at 31/12/2018	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	106,694	-	97,189

Details of any collateral

Nil.

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Q1 2019	Q1 2018
	S\$'000	S\$'000
Cash flows from operating activities		
Profit for the period	13,727	15,466
<i>Adjustments for :</i>		
Amortisation of intangible assets	347	361
Depreciation of property, plant and equipment	6,182	4,015
Equity-settled share-based payment transactions	378	575
Finance expenses	465	191
Finance income	(380)	(157)
Gain on disposal of property, plant and equipment	-	(44)
Property, plant and equipment written off	8	45
Tax expense	3,295	3,391
	<u>24,022</u>	<u>23,843</u>
<i>Changes in working capital :</i>		
Inventories	(566)	199
Trade and other receivables	(10,298)	(4,756)
Trade and other payables	(3,012)	(6,456)
Insurance contract provisions	13,696	14,051
Cash generated from operations	<u>23,842</u>	<u>26,881</u>
Tax paid	(1,410)	(2,661)
Interest paid	(749)	(258)
Net cash from operating activities	<u>21,683</u>	<u>23,962</u>
Cash flows from investing activities		
Acquisition of intangible assets	(225)	(211)
Interest received	365	158
Proceeds from sales of property, plant and equipment	-	45
Purchase of property, plant and equipment	(26,504)	(4,110)
Payment for investment properties under development	(7)	(17,575)
Net cash used in investing activities	<u>(26,371)</u>	<u>(21,693)</u>
Cash flows from financing activities		
Loan from subsidiary's non-controlling interest	2,023	-
Proceeds from issue of shares under share option scheme	596	299
Proceeds from bank loans	70,551	93,760
Repayment of bank loans	(61,717)	(101,148)
Payment of finance lease liabilities	(1,588)	-
Payment to restricted cash account	(1,085)	-
Net cash from/(used in) financing activities	<u>8,780</u>	<u>(7,089)</u>
Net increase/(decrease) in cash and cash equivalents	4,092	(4,820)
Cash and cash equivalents at 1 January	105,984	98,270
Effect of exchange rate fluctuations on cash held	664	558
Cash and cash equivalents at 31 March	<u>110,740</u>	<u>94,008</u>

Explanatory notes to the Statement of Cash Flows

The cash and cash equivalents for the statement of cash flows presentation excluded an amount of S\$1.1 million (US\$0.8 million) deposited in an escrow account of a subsidiary. The Group's cash and cash equivalents increased by S\$4.7 million from S\$106.0 million as at 31 December 2018 to S\$110.7 million as at 31 March 2019. This was mainly due to strong cashflows generated by the Group from operations and financing from bank loans, offset by capital expenditure for Raffles Hospital Shanghai and Raffles Hospital Chongqing.

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Group	Share capital S\$'000	Translation reserve S\$'000	Share option reserve S\$'000	Revaluation reserve S\$'000	Other reserve S\$'000	Accumulated profits S\$'000	Total attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
At 1 January 2018	340,201	(284)	26,194	1,712	(4,714)	370,941	734,050	17,575	751,625
Total comprehensive income for the period									
Profit for the period	-	-	-	-	-	15,812	15,812	(346)	15,466
Other comprehensive income									
Foreign currency translation differences - foreign operations	-	1,320	-	-	-	-	1,320	316	1,636
Total other comprehensive income for the period	-	1,320	-	-	-	-	1,320	316	1,636
Total comprehensive income for the period	-	1,320	-	-	-	15,812	17,132	(30)	17,102
Transactions with owners, recognised directly in equity									
Contributions by and distributions to owners									
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	299	-	-	-	-	-	299	-	299
Value of employee services received for issue of share options	-	-	575	-	-	-	575	-	575
Total contributions by and distributions to owners	299	-	575	-	-	-	874	-	874
Changes in ownership interests in subsidiaries									
Present value of the exercise price of written put options	-	-	-	-	769	-	769	-	769
Total changes in ownership interests in subsidiaries	-	-	-	-	769	-	769	-	769
Total transactions with owners	299	-	575	-	769	-	1,643	-	1,643
At 31 March 2018	340,500	1,036	26,769	1,712	(3,945)	386,753	752,825	17,545	770,370

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd).

Group	Share capital S\$'000	Translation reserve S\$'000	Share option reserve S\$'000	Revaluation reserve S\$'000	Other reserve S\$'000	Accumulated profits S\$'000	Total attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
At 1 January 2019	365,332	(6,131)	27,655	16,367	(4,741)	402,007	800,489	16,137	816,626
Total comprehensive income for the period									
Profit for the period	-	-	-	-	-	13,649	13,649	78	13,727
Other comprehensive income									
Foreign currency translation differences - foreign operations	-	3,359	-	-	-	-	3,359	356	3,715
Total other comprehensive income for the period	-	3,359	-	-	-	-	3,359	356	3,715
Total comprehensive income for the period	-	3,359	-	-	-	13,649	17,008	434	17,442
Transactions with owners, recognised directly in equity									
Contributions by and distributions to owners									
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	596	-	-	-	-	-	596	-	596
Value of employee services received for issue of share options	-	-	378	-	-	-	378	-	378
Total contributions by and distributions to owners	596	-	378	-	-	-	974	-	974
Changes in ownership interests in subsidiaries									
Present value of the exercise price of written put options	-	-	-	-	16	-	16	-	16
Total changes in ownership interests in subsidiaries	-	-	-	-	16	-	16	-	16
Total transactions with owners	596	-	378	-	16	-	990	-	990
At 31 March 2019	365,928	(2,772)	28,033	16,367	(4,725)	415,656	818,487	16,571	835,058

- 1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd).

Company	Share capital S\$'000	Share option reserve S\$'000	Accumulated profits S\$'000	Total S\$'000
At 1 January 2018	340,201	26,194	242,156	608,551
Total comprehensive income for the period				
Profit for the period	-	-	1,349	1,349
Total comprehensive income for the period	-	-	1,349	1,349
Transactions with owners, recognised directly in equity				
Contributions by and distributions to owners				
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	299	-	-	299
Value of employee services received for issue of share options	-	575	-	575
Total contributions by and distributions to owners	299	575	-	874
At 31 March 2018	340,500	26,769	243,505	610,774
At 1 January 2019	365,332	27,655	262,905	655,892
Total comprehensive income for the period				
Profit for the period	-	-	1,440	1,440
Total comprehensive income for the period	-	-	1,440	1,440
Transactions with owners, recognised directly in equity				
Contributions by and distributions to owners				
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	596	-	-	596
Value of employee services received for issue of share options	-	378	-	378
Total contributions by and distributions to owners	596	378	-	974
At 31 March 2019	365,928	28,033	264,345	658,306

- 1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

During the first quarter ended 31 March 2019, the Company issued a total of 938,000 new ordinary shares, upon the exercise of options under the Raffles Medical Group Share Option Schemes.

Exercise price per share	S\$0.26	S\$0.55	S\$0.73	S\$0.78	S\$1.07
Number of new shares issued	388,000	117,000	47,000	56,000	330,000

As at 31 March 2019, there were outstanding options for conversion into 63,964,000 (31 March 2018: 59,176,000) ordinary shares. The Company does not hold any treasury shares and there is no subsidiary holdings as at 31 March 2019 (31 March 2018: Nil).

- 1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at end of the immediately preceding year.**

	31/03/2019	31/12/2018
Number of issued shares excluding treasury shares	1,798,112,400	1,797,174,400

- 1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

There were no sales, transfers, cancellation and/or use of treasury shares as at 31 March 2019 (31 December 2018: Nil).

- 1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.**

There were no sales, transfers, cancellation and/or use of subsidiary holdings as at 31 March 2019 (31 December 2018: Nil).

- 2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

The financial statements on consolidated results for the first quarter ended 31 March 2019 have not been audited or reviewed.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Accounting policies and methods of computation used in the consolidated financial statements for the first quarter ended 31 March 2019 are consistent with those applied in the financial statements for the year ended 31 December 2018, except for the adoption of accounting standards (including its consequential amendments) and interpretations applicable for the financial period beginning 1 January 2019 as disclosed in item 5 below.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

The adoption of new and revised standards did not have substantial effect on the financial performance and position of the Group except for the adoption of Singapore Financial Reporting Standards (International) (SFRS(I)) 16 *Leases* which took effect on 1 January 2019, using the modified retrospective approach. In compliance with SFRS(I) 16 *Leases*, the Group has applied the practical expedient to recognise the amount of right-of-use assets equal to the lease liabilities, adjusted by the amount of accrued lease payment related to that lease recognised in the statement of financial position immediately before 1 January 2019.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	First Quarter	
	Q1 2019	Q1 2018
Earnings per ordinary share for the year based on 1(a) above :-		
(i) Basic earnings per share [A]	0.76 cents	0.89 cents
(ii) Diluted earnings per share [B]	0.76 cents	0.89 cents

[A] The calculation of earnings per ordinary share was based on weighted average number of shares 1,797,448,744 (Q1 2018: 1,771,407,703) in issue during the period.

[B] The calculation of earnings per ordinary share (on a fully diluted basis) was based on weighted average number of shares of 1,801,070,441 (Q1 2018: 1,776,206,536) in issue during the period.

7. **Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:-**

- (a) **current financial period reported on; and**
(b) **immediately preceding financial year.**

	Group		Company	
	31/03/2019	31/12/2018	31/03/2019	31/12/2018
Net asset value per ordinary share [C]	45.52 cents	44.54 cents	36.61 cents	36.50 cents

[C] The calculation of net asset value per ordinary share was based on 1,798,112,400 shares as at 31 March 2019 (31 December 2018: 1,797,174,400).

8. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-**

- (a) **any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
(b) **any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

The Group registered a quarterly revenue of **S\$128.3** million in Q1 2019 as compared to **S\$120.2** million in Q1 2018. Revenue for Healthcare Services division and Hospital Services division grew by **8.9%** and **3.2%** respectively. Increase in revenue from Healthcare Services division was contributed mainly by increase in premium from existing and new clients, Primary Care Network (PCN) Scheme and projects. The growth in revenue from the Hospital Services division was contributed mainly by higher utilisation of inpatient capacities.

The Group's earnings before interest, taxes, depreciation and amortisation (**EBITDA**) increased by **1.6%** from **S\$23.3** million in Q1 2018 to **S\$23.6** million for Q1 2019. The net profit after tax decreased to **S\$13.7** million in Q1 2019, due to start-up costs for **RafflesHospital Chongqing**. On a comparable basis, excluding the results of **RafflesHospital Chongqing**, the Group's net profit after tax would have grown by **2.1%** instead of a decrease of **11.2%** and EBITDA would have been **S\$25.4** million, an increase of **9.3%** as compared to Q1 2018. The gestation loss for **RafflesHospital Chongqing** is within expectation.

The continued strong operating cashflows generated from the Group's business operations contributed to a healthy cash position of **S\$111.8** million. This was after accounting for the payment of **S\$26.5** million for fixed assets under development as well as capital expenditure in the first quarter of this year.

9. **Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

The current financial period's results are in line with the Directors' expectations as disclosed in the Group's full year 2018 results announcement.

10. **A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

Since opening its doors on 2 January 2019, **RafflesHospital Chongqing** had embarked on outreach programmes to companies, embassies and business associations. Concurrently, it had also rolled out a series of marketing campaigns to raise its brand awareness in Chongqing. This included the co-sponsoring Chongqing International Marathon, an international sporting event attracting about 30,000 runners and receiving wide media coverage.

RafflesHospital Singapore officially opened its new block **RafflesSpecialistCentre** in March 2019. The complex with ambulatory and inpatient services from 31 different specialties, positions the Group's flagship as a one-stop healthcare hub, providing services for our patients, both local and overseas as well as corporate partners. **RafflesSpecialistCentre** enables the Group to continue to provide quality care and service to our customers in a seamless manner.

RafflesMedical was awarded a new tender to provide institutional medical services under the Ministry of Social and Family Development (MSF). Another eight **RafflesMedical** clinics were added to the current panel of 40 Primary Care Network (PCN) clinics to enhance convenience to more patients in the heartlands for chronic disease care.

RafflesMedical started its journey on digitalisation and innovation to improve patient experience and healthcare access for both treatment and wellness services. Through the secure **RafflesConnect** platform, patients can consult a doctor via the 24/7 tele-consultation service, and have their medication delivered to them directly. This platform was officially launched in January 2019 where patients can also access their health records, receive health advisories, personalised health tips, and select a suite of services online in one integrated e-healthcare platform.

RafflesHealthinsurance is enhancing its overall value proposition to its customers through the introduction of the digital platform, **RafflesConnect**. The digital solution allows the insured to submit their claims and check their claims' status online. It also enables patients to make appointment with their doctors, access to tele-consultation service and personalised health information, bringing seamless experience to the customers.

While construction of **RafflesHospital Shanghai**, in Pudong, is underway, preparatory works for commissioning and operational phase has begun in Singapore.

Based on the current economic conditions and barring unforeseen circumstances, the Directors expect the Group to grow its revenue and remain profitable in 2019, notwithstanding the expected gestation loss for **RafflesHospital Chongqing**.

11. Dividend

(a) Current Financial Period Reported On

Any dividend declared for the current financial period reported on? No

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year? No

(c) Date payable

Not applicable.

(d) Books closure date

Not applicable.

12. If no dividend has been declared/recommendeded, a statement to that effect.

No dividend has been declared or recommended for the first quarter ended 31 March 2019.

13. If the group has obtained a general mandate from shareholders for Interested Parties Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company did not obtain a general mandate from shareholders for IPTs.

14. Confirmation pursuant to Rule 705 (5) of the Listing Manual

To the best of our knowledge, nothing has come to the attention of the Board of Directors, which may render the unaudited interim financial statements of the Group and the Company for the first quarter ended 31 March 2019 to be false or misleading in any material aspect.

15. Confirmation pursuant to Rule 720 (1) of the Listing Manual

The Company confirms that it has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7.7) under Rule 720 (1) of the Listing Manual.

BY ORDER OF THE BOARD

Kimmy Goh
Company Secretary
29 April 2019